会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明公开
    • PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME
    • 印度尼西亚反犹太人解放阵线
    • EP0757051A1
    • 1997-02-05
    • EP96902477.7
    • 1996-02-19
    • SUNTORY LIMITED
    • ISHIGURO, MasajiNAKATSUKA, TakashiTANAKA, RieNAMIKAWA, KoshiMATSUKI, Shinsuke
    • C07D499/88A61K31/43
    • C07D499/88Y02P20/55
    • A penem derivative represented by the following formula (I):
      wherein R 1 represents a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted alkylthio group, a substituted or unsubstituted alkenylthio group, a substituted or unsubstituted aralkylthio group, a substituted or unsubstituted arylthio group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted heterocyclic thio group, a substituted or unsubstituted acylthio group, a mercapto group or a hydrogen atom, and R 2 represents a hydrogen atom or a carboxyl-protecting group; or a pharmacologically acceptable salt thereof.
      The compound (I) exhibits strong antibacterial activities, and especially, shows strong activities against MRSA. It is therefore useful not only as a general antibacterial agent but also as an antibacterial agent for MRSA against which no general antibacterial agents are recognized to be effective.
    • 由下式(I)表示的pen嗪衍生物:其中R 1表示取代或未取代的烷基,取代或未取代的烯基,取代或未取代的芳烷基,取代或未取代的芳基,取代或未取代的芳基 取代或未取代的芳硫基,取代或未取代的芳硫基,取代或未取代的杂环基,取代或未取代的杂环硫基,取代或未取代的酰硫基,巯基或巯基 氢原子,R 2表示氢原子或羧基保护基; 或其药理学上可接受的盐。 化合物(I)表现出强烈的抗菌活性,特别是对MRSA具有强烈的活性。 因此,不仅可以作为普通抗菌剂,而且作为MRSA的抗菌剂也是有用的,因为没有一般的抗菌剂被认为是有效的。
    • 6. 发明公开
    • PROCESS FOR SYNTHESIZING 4-SUBSTITUTED AZETIDINONE DERIVATIVE
    • 合成4-取代的二氮杂萘酮衍生物的方法
    • EP0638552A1
    • 1995-02-15
    • EP94906364.8
    • 1994-02-10
    • SUNTORY LIMITED
    • ISHIGURO, MasajiNAKATSUKA, TakashiTANAKA, RieSHIMAMOTO, TetsuoYOSHIDA, Takuro
    • C07D205/08
    • C07D205/08
    • The invention relates to a process for synthesizing a 4-substituted azetidinone derivative represented by the general formula (3) (wherein OR₁ represents a protected hydroxyl group; CO₂R₃ represents an esterified carboxyl group; and X and Y represent each independently alkyl, alkenyl, aralkyl, aryl, alkylthio, alkoxy, heterocycle, acyl, amino, hydrogen or halogen, or alternatively X and Y are combined together to represent cycloalkan-2-on-2-yl) by the reaction of an azetidinone derivative represented by general formula (1) (wherein OR₁ is as defined above; and R₂ represents alkyl, alkenyl or aryl) with an ester compound represented by general formula (2): (wherein CO₂R₃, X and Y are each as defined above) in the presence of zinc and copper compounds. The invention relates also to a compound represented by general formula (3) and further to a compound prepared by decarboxylating the compound (3), both being useful as an intermediate for synthesizing antibacterial carbapenem compounds.
    • 本发明涉及由通式(3)表示的4-取代氮杂环丁酮衍生物的合成方法(式中OR 1代表被保护的羟基; CO 2 R 3代表酯化的羧基; X和Y分别独立地代表烷基,链烯基,芳烷基 (1)所示的氮杂环丁酮衍生物与式(1)所示的氮杂环丁酮衍生物反应,从而得到式(1)所示的环烷基-2-酮基 )(其中OR 1定义如上; R 2代表烷基,链烯基或芳基)与通式(2)代表的酯化合物反应:(其中CO 2 R 3,X和Y的定义同上)在锌和铜 化合物。 本发明还涉及由通式(3)表示的化合物,还涉及通过使化合物(3)脱羧而制备的化合物,两者都可用作用于合成抗菌碳杂青霉烯化合物的中间体。
    • 7. 发明公开
    • G PROTEIN-COUPLED RECEPTOR STRUCTURAL MODEL AND A METHOD OF DESIGNING LIGAND BINDING TO G PROTEIN-COUPLED RECEPTOR BY USING THE STRUCTURAL MODEL
    • 结构模型配体的设计结合G蛋白偶联受体使用结构模型A G蛋白偶联受体和方法
    • EP1376132A1
    • 2004-01-02
    • EP02708749.3
    • 2002-04-01
    • SUNTORY LIMITED
    • ISHIGURO, Masaji
    • G01N33/566G01N33/48G06F17/50G06F17/30C07K1/00
    • G06F19/12C07K14/723C07K2299/00G01N33/566G01N33/6803G06F19/16
    • The present invention provides a method for constructing a structural model of a complex that a G protein-coupled protein receptor forms with a ligand capable of binding the G protein-coupled receptor and a three-dimensional structural model of an activated intermediate in the structural model of the complex. The present invention also provides a method for identifying, screening for, searching for, evaluating, or designing a ligand capable of binding a GPCR by using the three-dimensional model. In one specific method provided by the present invention, a three-dimensional structural model of a photoactivated intermediate of rhodopsin is constructed by using a molecule modeling software and by using the three-dimensional structural coordinate of the crystal structure of rhodopsin in such a manner that amino acid residues highly conserved among GPCRs are taken into consideration. The three-dimensional stractural model of the photoactivated intermediate of rhodopsin is subsequently used to construct structural models of activated intermediates of other GPCRs. The present invention further provides a method for identifying, screening for, searching for, evaluating, or designing a ligand that binds a GPCR to act as an agonist or an antagonist. This method employs the three-dimensional structural model constructed by the above-described method.
    • 本发明提供的方法用于构造复杂的结构模型做了G蛋白偶联蛋白受体与配体能够结合G蛋白偶联受体,并在结构模型活化的中间体的三维结构模型 复杂。 因此,本发明提供了用于鉴定,筛选,寻找,评价,或设计能够通过使用三维模型结合GPCR的配体的方法。 在由本发明提供的一种具体方法,光活化的中间视紫红质的三维结构模型是通过使用分子建模软件并通过使用视紫质的晶体结构的三维结构坐标在寻求的方式做了构筑 的GPCR之间高度保守的氨基酸残基被考虑在内。 所述光活化stractural中间视紫质的三维模型随后用于构建其它GPCR的活化中间体的结构模型。 本发明进一步提供了用于鉴定,筛选,寻找,评价,或设计配体做的方法结合GPCR的充当到激动剂或拮抗剂。 该方法采用由上述方法构成的三维结构模型。